Meta-analysis of epidemiological studies demonstrates significant association of PTGS2 polymorphism rs689470 and no significant association of rs20417 with prostate cancer

Genetics and Molecular Research

Volumn 11, Issue 2, 2012, Pages 1642-1650

  Zhang, H T ^a   Xu, Y ^a   Zhang, Z H ^a   Li, L ^b  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Genetic polymorphisms; Meta analysis; Prostate cancer; PTGS2

Indexed keywords

CYCLOOXYGENASE 2;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; POPULATION GENETICS; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 2 GENE; PROSTATE CANCER;

EID: 84930484782     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2012.June.15.13     Document Type: Article

References (32)

1. Balistreri CR, Caruso C, Carruba G, Miceli V, et al. (2010). A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications. Curr. Pharm. Des. 16: 718-724.
2. Cao H, Xu Z, Long H, Li XQ, et al. (2010). The-765C allele of the cyclooxygenase-2 gene as a potential risk factor of colorectal cancer: a meta-analysis. Tohoku J. Exp. Med. 222: 15-21.
3. Cheng I, Liu X, Plummer SJ, Krumroy LM, et al. (2007). COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br. J. Cancer 97: 557-561.
4. Danforth KN, Hayes RB, Rodriguez C, Yu K, et al. (2008). Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis 29: 568-572.
5. Der Simonian R and Laird N (1986). Meta-analysis in clinical trials. Control Clin. Trials 7: 177-188.
6. Dossus L, Kaaks R, Canzian F, Albanes D, et al. (2010). PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 31: 455-461.
7. Egger M, Davey SG, Schneider M and Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
8. Gupta S, Srivastava M, Ahmad N, Bostwick DG, et al. (2000). Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 73-78.
9. Hiatt RA, Armstrong MA, Klatsky AL and Sidney S (1994). Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States). Cancer Causes Control 5: 66-72.
10. Hori S, Butler E and McLoughlin J (2011). Prostate cancer and diet: food for thought? BJU Int. 107: 1348-1359.
11. Ioannidis JP, Boffetta P, Little J, O'Brien TR, et al. (2008). Assessment of cumulative evidence on genetic associations: interim guidelines. Int. J. Epidemiol. 37: 120-132.
12. Kirschenbaum A, Klausner AP, Lee R, Unger P, et al. (2000). Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56: 671-676.
13. Kosaka T, Miyata A, Ihara H, Hara S, et al. (1994). Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem. 221: 889-897.
14. Lee LM, Pan CC, Cheng CJ, Chi CW, et al. (2001). Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res. 21: 1291-1294.
15. Liang Y, Liu JL, Wu Y, Zhang ZY, et al. (2011). Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: a meta-analysis. Tohoku J. Exp. Med. 223: 137-144.
16. Liu JL, Liang Y, Wang ZN, Zhou X, et al. (2010). Cyclooxygenase-2 polymorphisms and susceptibility to gastric carcinoma: a meta-analysis. World J. Gastroenterol. 16: 5510-5517.
17. Madaan S, Abel PD, Chaudhary KS, Hewitt R, et al. (2000). Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int. 86: 736-741.
18. Mahmud S, Franco E and Aprikian A (2004). Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br. J. Cancer 90: 93-99.
19. Mantel N and Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22: 719-748.
20. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, et al. (2000). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60: 1306-1311.
21. McArdle PA, Mir K, Almushatat AS, Wallace AM, et al. (2006). Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol. Int. 77: 127-129.
22. Murad A, Lewis SJ, Smith GD, Collin SM, et al. (2009). PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis. Prostate Cancer Prostatic Dis. 12: 296-300.
23. O'Byrne KJ and Dalgleish AG (2001). Chronic immune activation and inflammation as the cause of malignancy. Br. J. Cancer 85: 473-483.
24. Panguluri RC, Long LO, Chen W, Wang S, et al. (2004). COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25: 961-966.
25. Shacter E and Weitzman SA (2002). Chronic inflammation and cancer. Oncology 16: 217-26, 229.
26. Shahedi K, Lindstrom S, Zheng SL, Wiklund F, et al. (2006). Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int. J. Cancer 119: 668-672.
27. Tsujii M and DuBois RN (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501.
28. Uotila P, Valve E, Martikainen P, Nevalainen M, et al. (2001). Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol. Res. 29: 23-28.
29. Wu GY, Hasenberg T, Magdeburg R, Bonninghoff R, et al. (2009). Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J. Surg. 33: 124-129.
30. Wu HC, Chang CH, Ke HL, Chang WS, et al. (2011). Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in taiwan. Anticancer Res. 31: 221-225.
31. Yoshimura R, Sano H, Masuda C, Kawamura M, et al. (2000). Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89: 589-596.
32. Yu KD, Chen AX, Yang C, Qiu LX, et al. (2010). Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res. Treat. 122: 251-257.